Two days ago, the Infectious Disease Society (IDSA) published its recommendations against the use of Hydroxychloroquine and convalescent plasma for the treatment of COVID-19. Apparently, they knew that Trump would announce the FDA authorization of plasma therapy for COVID-19, and they wanted to strike preemptively. At the same time, they recommended the use of the ineffective and unsafe drug, Remdesivir.
IDSA justified its recommendation against HCQ by repeating earlier lies and fallacies. It disregarded real-world evidence, and commingled differing treatment regimens including HCQ into one – as if all treatment regimens, time of administration and dosages were the same.They presented a review that included already refuted failures and frauds (Magagnoli, Geleris, Mahevas, Rosenberg, etc.), and excluded large studies showing great effectiveness of Hydroxychloroquine + Azithromycin treatment. Here are just some of the excluded studies: